Pharmacy News

Entries for October 2016

Blood Pressure and Medication – JNC 8 Highlights

The Eighth Joint National Committee (JNC 8) updates to hypertension guidelines brought changes in the approach toward treatment and pharmacotherapy. Many of these changes differed from the previous adhered to recommendations (JNC 7) for the treatment of high blood pressure. Understanding the changing recommendations is always important to ensure patients are receiving the highest quality treatment and approach to managing their condition.

Here are some of the primary changes in JNC 8 that deviate from the JNC 7:1
  1. Patients 60 years and older who do not have diabetes or a chronic disease should have a goal blood pressure level that is now <150/90 mmHg
  2. Patients 18 to 59 without major comorbidities, and patients 60 years of age or older who do have diabetes or chronic kidney disease (or both), the new goal blood pressure level is <140/90 mmHg
  3. First and later-line treatments should be limited to four medication classes: thiazide-type diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)
  4. Second and third-line alternatives include higher doses or combinations of ACEIs, ARBs, thiazide-type diuretics and CCBs
    1. Several medications have been designated as later-line alternatives:
    2. Beta-blockers
    3. Alpha-blockers
    4. Alpha1/beta-blockers (e.g. carvedilol)
    5. Vasodilating beta-blockers (e.g., nevivolol)
    6. Central alpha2-adrenergic agonists (e.g., clonidine)
    7. Direct vasodilators (e.g., hydralazine)
    8. Loop diuretics (e.g., furosemide)
    9. Aldosterone antagonists (e.g., spironolactone)
    10. Peripherally acting adrenergic antagonists (e.g., reserpine)
  5. When beginning therapy in patients of African ancestry without chronic disease should use CCBs and thiazides instead of ACEIs
  6. Use of ACEIs and ARBs is recommended in all patients with chronic kidney disease regardless of ethnic background, either as first-line therapy or in addition to first-line therapy.
  7. ACEIs and ARBs should not be used in the same patient simultaneously
  8. CCBs and thiazide-type diuretics should be used instead of ACEIs and ARBs in patients over the age of 75 with impaired kidney function due to risk of hyperkalemia, increase creatinine and renal impairment

Some of these new guidelines may go against what were the previously established norms, particularly in reference to a less stringent systolic blood pressure which may puzzle some pharmacists and patients. The shift in focusing on a diastolic blood pressure goal will ideally lead to less medication therapy in younger patients with an early diagnosis thereby increase the level of adherence to prescribed medications and minimize adverse side effects associated with low systolic blood pressure.

References:
  1. Page MR. The JNC 8 Hypertension Guidelines: An In-Depth Guide. PharmacyTimes.com. http://www.pharmacytimes.com/news/the-jnc-8-hypertension-guidelines-an-in-depth-guide. Published Jan. 6, 2014. Accessed October 2016.
Posted in: Professional Practice
MSHP Professional Practice Award

FOR IMMEDIATE RELEASE
Oct. 27, 2016
Contact: Kristina Bird, communications manager
(517) 377-0232

 

Professional Practice Award given to Dorsch for Involvement in New Adherence Approaches

 

Lansing, Mich. – Michael Dorsch, Pharm.D., M.S., FCCP, BCPS (AQCV), will receive the 2016 Michigan Society of Health-System Pharmacists (MSHP) Professional Practice Award at this year’s MSHP Annual Meeting on Oct. 28.

 

The MSHP Professional Practice Award recognizes and honors a pharmacist or organization for involvement and participation in an innovative project (e.g., published research, projects or services implemented) that contributes to professional practice. This year’s recipient is being honored for his work supporting the mission of the American Heart Association (AHA) to build healthier lives that are free of cardiovascular disease and stroke. More specifically, Dr. Dorsch has developed a mobile application for heart failure patients, ManageHF, aimed at educating patients in order to increase the adherence and efficacy of recommended treatments for cardiovascular diseases.

 

Michael Dorsch currently has over 40 peer-reviewed publications, one book and has conducted over 18 national presentations. In 2011, Dr. Dorsch received the Top Paper Award for Population Science at the AHA Council for High Blood Pressure Research Conference. In this paper Dr. Dorsch demonstrated the superior efficacy of chlorthalidone in reducing cardiovascular events in hypertension and this discovery was ultimately included in the European Society of Cardiology (ESC) Hypertension guidelines. Currently, the Agency for Healthcare Research and Quality (AHRQ) is funding Dr. Dorsch’s work to create a mobile application to assist patients in making better and more informed decisions while shopping at the grocery store and dining out while adhering to a low sodium diet. The National Institutes of Health (NIH) has also supported Dr. Dorsch in creating technology to increase self-monitoring and self-management of heart failure patients, increasing adherence to diet restriction for hypertension patients and an automated home medication dispensing machine.

 

Dr. Dorsch currently works as a clinical associate professor at the University of Michigan (UM) College of Pharmacy and is also a clinical pharmacist in cardiology at the Department of Pharmacy Services UM Health System, Ann Arbor, Mich. In this position, Dr. Dorsch provides inpatient pharmacy services to cardiology patients at the UM Frankel Cardiovascular Center as well as coordinating cardiology courses at the UM College of Pharmacy. Dr. Dorsch is also a site preceptor for the American College of Clinical Pharmacy (ACCP) HF Traineeship and created the Post-Graduate Year 2 Cardiology Residency Program at UM in 2008 and has been serving as the director ever since. Dr. Dorsch has dedicated his life to educating patients and empowering them to make the best decisions for their health.

 

MSHP is a practice section of MPA consisting of more than 600 health-system pharmacy professionals. Since its founding in 1883, MPA has been a leader in the professional and scientific advancement of pharmacy and in safeguarding the well-being of individual patients in Michigan.

 

###

Posted in: MPA Press Releases
MSHP President's Award

FOR IMMEDIATE RELEASE
Oct. 27, 2016
Contact: Kristina Bird, communications manager
(517) 377-0232

 

Hae Mi Choe presented with President’s Award for

Innovative Practice Model Implementation

Lansing, Mich. – Hae Mi Choe, Pharm.D. will be honored with this year’s Michigan Society of Health-System Pharmacists (MSHP) President’s Award at the 2016 MSHP Annual Meeting on Oct. 28.

The MSHP President’s Award recognizes the commitment of a pharmacy professional or a pharmacy organization to advancing the theme and goal of the MSHP Board of Directors throughout the year. This year, MSHP has focused on provider status and the concept of “Changing Gears.” As the terrain of pharmacy continues to shift, and the direction of the profession heads toward new frontiers, Hae Mi Choe has established herself as a pioneer in her work to advance the role of pharmacists in the ambulatory care setting. Dr. Choe is recognized by her colleagues as an incredible innovator as well as a strong supporter through hands on assistance and mentorship of colleagues advancing their practice. They also note she is kind, organized and approachable. Consistent with this year’s theme, the work Dr. Choe has done, and continues to do, creates a framework for pharmacists to practice as providers to improve the overall care of patients. It also serves as an inspiration and model for future pharmacists to practice in these advanced roles.

Dr. Choe received her baccalaureate degree in Biochemistry/Cell Biology from the University of California, San Diego and her Doctor of Pharmacy degree from the University of California, San Francisco. She completed her Pharmacy Practice Residency at Kaiser Permanente in Los Angeles. After residency, she moved to Seoul, South Korea, and developed and implemented anticoagulation and asthma services at the Samsung Medical Center. After five years overseas, Dr. Choe joined the faculty at the University of Michigan Health System (UMHS) to develop ambulatory clinical services. In 2009, Dr. Choe was promoted to the position of Director of Innovative Ambulatory Care Pharmacy Practices at UMHS. In this role, she created a group practice model at UMHS as part of the Patient Centered Medical Home across 14 health centers, as well as a new reimbursement process for clinical pharmacy services. She was the first pharmacist evaluated and endorsed by the Credentialing Committee at UMHS and was granted special privileges in patient care; she has since led her entire team of clinical pharmacists through the credentialing process. Dr. Choe has been recognized numerous times throughout her career for both her excellence in teaching as well as for her work in developing innovative practice models. Notably, in 2011 she and her colleagues were awarded both the MPA Innovative Pharmacy Practice Award and the ASHP Best Practice Award for their group practice model in the Patient-Centered Medical Home. In 2014, Dr. Choe received the American Pharmacists Association (APhA) Pinnacle Award in the Individual Career Achievement category.

As part of her current role, Dr. Choe has been instrumental in the development and launch of the Michigan Pharmacists Transforming Care and Quality (MPTCQ) Collaborative Process Initiative (CPI) program, a collaboration between Blue Cross and Blue Shield of Michigan (BCBSM) and UMHS which aims to integrate clinical pharmacists into more direct patient care roles. This program, which was modeled after the program Dr. Choe built at UMHS, has brought clinical pharmacy services to 17 health-system or physician group practices throughout the state, which encompasses over 50 individual practice sites, all with a goal of improving patient care through pharmacist-physician collaboration. The program continues to expand, with the intent to implement it in all 46 health-system or physician group practices that work with BCBSM over the next several years.

 

MSHP is a practice section of the Michigan Pharmacists Association consisting of more than 600 health-system pharmacy professionals. Since its founding in 1883, MPA has been a leader in the professional and scientific advancement of pharmacy and in safeguarding the well-being of individual patients in Michigan.

 

###

Posted in: MPA Press Releases
MSHP Pharmacist of the Year

 

FOR IMMEDIATE RELEASE
Oct. 27, 2016
Contact: Kristina Bird, communications manager
(517) 377-0232


Ruffing to be Honored as Michigan Health-System

Pharmacist of the Year 

Lansing, Mich. – Michael J. Ruffing, Pharm.D. will be honored as the 2016 Michigan Society of Health-System Pharmacists (MSHP) Pharmacist of the Year at the Society’s Annual Meeting on Oct. 28.

 

Dr. Ruffing has spent his career working to continually advance opportunities for pharmacists and helping to create the most prepared pharmacists for the future of the profession. Dr. Ruffing is active in many local, state and national pharmacy associations, and has served MSHP as a Director on the Board and as President. He also extended his service to the Southeastern Michigan Society of Health-System Pharmacists (SMSHP) as a Board member and President. Dr. Ruffing is also extensively involved with the American Society of Health-System Pharmacists (ASHP), most notably as a participant at the ASHP Ambulatory Care Summit in 2014. That same year, Dr. Ruffing was also a key organizer in the 2014 MSHP Ambulatory Care Summit. Beyond his work with ASHP, Dr. Ruffing has served as the SMSHP representative to the Michigan Pharmacists Association (MPA) House of Delegates and has sat as Chair for the MSHP Professional and Legal Affairs Committee.

Dr. Ruffing graduated from West Virginia University College of Pharmacy and earned his Pharm.D. degree from the Medical University of South Carolina. At Allegheny General Hospital in Pittsburg, Penn., Dr. Ruffing completed a General Pharmacy Residency followed by a Critical Specialty Residency at the Medical College of Virginia in Richmond. Dr. Ruffing has worked as a clinical pharmacist specialist in critical care as well as a clinical coordinator and pharmacy manager at Detroit Receiving Hospital before becoming the Director of Pharmacy Services at Sinai-Grace Hospital. Throughout his career he has precepted students and residents in critical care, participated in research and published several articles and written textbook chapters. Dr.  Ruffing has participated in the Michigan Make-A-Wish Foundation’s Wish-A-Mile Bicycle Tour, a three-day, 300 mile bike ride from Brooklyn, Mich. to Traverse City, ultimately combining his love of cycling with his unmatched ability to give back and serve those around him.

MSHP is a practice section of MPA consisting of more than 600 health-system pharmacy professionals. Since its founding in 1883, MPA has been a leader in the professional and scientific advancement of pharmacy and in safeguarding the well-being of individual patients in Michigan.

 

###

Posted in: MPA Press Releases
MSHP Joseph A. Oddis Leadership Award

 

FOR IMMEDIATE RELEASE
Oct. 27, 2016
Contact: Kristina Bird, communications manager
(517) 377-0232

 

Malovrh Honored for her Ongoing Commitment and Dedication

to the Society and Michigan Pharmacists

Lansing, Mich. – Margaret A. Malovrh, Pharm.D., BCPS will receive the 2016 Joseph A. Oddis Leadership Award at the Michigan Society of Health-System Pharmacists (MSHP) Annual Meeting on Oct. 28. Recipients of this award must be active in association work, be a member of MSHP and display leadership qualities.

 

Dr. Malovrh is being recognized as the recipient of this award for her ongoing and continual commitment to MSHP, the Association and the profession as a strong advocate and leader. Dr. Malovrh has been an active member in the Association since joining in 1980. Over the last 30 years, Dr. Malovrh has continually helped lead the Society and Association in all its activities and goals. Namely, Dr. Malovrh has served as president of both the Capital Area Pharmacists Association (CAPA) and MSHP. Previously, she has served on several MSHP committees and even sat as the Chair for the MSHP Organizational Affairs Committee. Dr. Malovrh is currently serving on the Michigan Pharmacists Association (MPA) Executive Board. Outside of her membership with MPA, Dr. Malovrh has also been a member of the American Society of Health-System Pharmacists (ASHP) since 1981 and the American College of Clinical Pharmacy (ACCP) since 1998. Dr. Malovrh has also served as delegates to both the ASHP House of Delegates as well as to the MPA House of Delegates.

Dr. Malovrh received her Bachelor of Science degree in 1980 from Ferris State University (FSU) and continued on to earn her Doctor of Pharmacy in 1993 also from Ferris. She became a member of MPA as soon as she completed her undergraduate education. Currently she serves as the clinical coordinator and pharmacy resident director at the Sparrow Health System in Lansing, a position she’s held since 2007. Dr. Malovrh is also a preceptor for students from University of Michigan (UM), Wayne State University (WMU) and FSU. She is board certified in pharmacotherapy, and has earned the Fellow of the MPA distinction for her continual work in preparing pharmacy students and leading the profession over the last 30 years.

MSHP is a practice section of MPA consisting of more than 600 health-system pharmacy professionals. Since its founding in 1883, MPA has been a leader in the professional and scientific advancement of pharmacy and in safeguarding the well-being of individual patients in Michigan.

 

###

Posted in: MPA Press Releases
Page 1 of 7First   Previous   [1]  2  3  4  5  6  7  Next   Last